Noile-Immune Biotech Inc. (JP:4893)
:4893
Top Page
Noile-Immune Biotech Inc.
(4893)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥149.00
▲(11.19% Upside)
Action:ReiteratedDate:03/12/26
The score is primarily weighed down by weak financial performance—shrinking revenue, large losses, and ongoing cash burn—partly offset by a debt-free balance sheet. Technicals are neutral-to-soft with limited momentum, and valuation lacks support given negative earnings and no dividend yield.
Positive Factors
Debt-free balance sheet
Having no debt materially reduces solvency and interest-cost risk over the medium term, preserving flexibility to fund R&D or clinical programs via equity or cash reserves. This durable capital-structure strength lowers bankruptcy risk while the company pursues clinical milestones.
Negative Factors
Sharply contracting revenue
A sustained, steep revenue decline undermines the commercialization trajectory and operating leverage. Persistently shrinking top line reduces ability to absorb fixed R&D/G&A, impairs internal funding capacity, and raises execution risk for clinical and commercial milestones over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Having no debt materially reduces solvency and interest-cost risk over the medium term, preserving flexibility to fund R&D or clinical programs via equity or cash reserves. This durable capital-structure strength lowers bankruptcy risk while the company pursues clinical milestones.
Read all positive factors
Noile-Immune Biotech Inc. (4893) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.66B
Dividend YieldN/A
Average Volume (3M)85.17K
Price to Earnings (P/E)―
Beta (1Y)1.46
Revenue Growth-12.01%
EPS Growth26.66%
CountryJP
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.36
Shares Outstanding43,276,764
10 Day Avg. Volume110,290
30 Day Avg. Volume85,173
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.46
Price to Sales (P/S)1151.82
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-34
Revenue Forecast (FY)¥300.00M
Noile-Immune Biotech Inc. Business Overview & Revenue Model
Company Description
Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan....
How the Company Makes Money
null...
Noile-Immune Biotech Inc. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.14M | 5.00M | 7.59M | 316.82M | 625.78M | 100.73M |
| Gross Profit | 9.14M | 5.00M | 7.39M | 314.56M | 618.71M | 77.83M |
| EBITDA | -519.02M | -797.25M | -1.07B | -775.39M | -106.34M | -767.51M |
| Net Income | -692.16M | -793.54M | -964.46M | -1.13B | -386.62M | -795.03M |
Balance Sheet | ||||||
| Total Assets | 4.38B | 4.01B | 4.80B | 5.78B | 4.64B | 4.27B |
| Cash, Cash Equivalents and Short-Term Investments | 4.31B | 3.92B | 4.67B | 5.56B | 4.52B | 4.14B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 68.07M | 79.64M | 74.67M | 91.49M | 340.42M | 85.72M |
| Stockholders Equity | 4.31B | 3.93B | 4.73B | 5.69B | 4.30B | 4.19B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 0.00 | -887.81M | -873.08M | -107.18M | -777.14M |
| Operating Cash Flow | 0.00 | -752.22M | -887.81M | -873.08M | -107.18M | -777.14M |
| Investing Cash Flow | 0.00 | -378.00K | 557.00K | -5.32M | 0.00 | -4.03M |
| Financing Cash Flow | 0.00 | -20.00K | 2.50M | 1.91B | 487.62M | 2.37B |
Noile-Immune Biotech Inc. Technical Analysis
Negative
134.00
Price Trends
155.68
Negative
151.97
Negative
163.69
Negative
Market Momentum
0.59
Positive
45.61
Neutral
5.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4893, the sentiment is Negative. The current price of 134 is below the 20-day moving average (MA) of 161.75, below the 50-day MA of 155.68, and below the 200-day MA of 163.69, indicating a bearish trend. The MACD of 0.59 indicates Positive momentum. The RSI at 45.61 is Neutral, neither overbought nor oversold. The STOCH value of 5.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4893.
Noile-Immune Biotech Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥7.78B | 59.41 | ― | 1.24% | -14.78% | -95.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥12.12B | -8.14 | ― | ― | -42.49% | -2.37% | |
48 Neutral | ¥6.66B | -7.26 | ― | ― | -12.01% | 26.66% | |
46 Neutral | ¥8.06B | -7.89 | -63.25% | ― | 99.87% | 40.60% | |
45 Neutral | ¥18.87B | -11.30 | ― | ― | ― | 11.34% | |
43 Neutral | ¥7.94B | -10.09 | ― | ― | -93.79% | -1332.86% |
* Healthcare Sector Average
JP:4893
Noile-Immune Biotech Inc.
154.00
-16.00
-9.41%
JP:4564
OncoTherapy Science
21.00
-7.00
-25.00%
JP:3750
Cytori Cell Research Institute, Inc.
889.00
-34.00
-3.68%
JP:4599
StemRIM Inc.
301.00
-53.00
-14.97%
JP:4880
CellSource Co., Ltd.
392.00
-395.10
-50.20%
JP:7776
CellSeed Inc.
315.00
-209.00
-39.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.